Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Fully Closed Loop Artificial Pancreas System for Type 1 Diabetes

FY 2023-24

Summary
Individuals with Type 1 Diabetes do not produce the hormone, insulin which maintains normal blood sugar levels. Consequently, they must be supplied with exogenous insulin based on the carbohydrate content of their meals. However, carbohydrate counting is error-prone, resulting in sub-optimal glucose control. Type 1 Diabetics are also deficient in the hormone, amylin which helps regulate blood sugar levels by delaying food absorption, glucagon secretion and increasing satiety. The synthetic analog of amylin, pramlintide, is FDA-approved. We aim to conduct a clinical trial to alleviate carbohydrate counting using our novel fully closed loop automated insulin delivery system (AID) with pramlintide as an adjunctive therapy. Participants will use a continuous glucose monitor, insulin and pramlintide pumps and our EuGlide application. Our AID system will integrate these devices to automate insulin (and pramlintide) delivery based on an individual’s glucose readings with no user input required. In this cross-over trial, 30 adults with type 1 diabetes will undergo three weeks of each of the following interventions, fully automated insulin-and-pramlintide delivery at (i) 8µg/u and (ii) 10 µg/u ratios and (iii) hybrid automated insulin-and-placebo delivery system with carbohydrate counting. Participants will undergo interviews and questionnaires to assess psychosocial outcomes and their quality of life. If our study shows non-inferiority in the time in target range between interventions, we conclude that the fully automated insulin-and-pramlintide delivery system does not degrade glucose outcomes compared to the hybrid automated delivery system. We hope that our novel AID system eliminates carbohydrate counting and alleviates disease burden by automating insulin delivery.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506023
Name
Doumat Joelle
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Fully Closed Loop Artificial Pancreas System for Type 1 Diabetes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Artificial Pancreas System; Carbohydrate Counting; Fully Closed Loop System; Insulin; Pramlintide; Type 1 Diabetes
Abstract
Individuals with Type 1 Diabetes do not produce the hormone, insulin which maintains normal blood sugar levels. Consequently, they must be supplied with exogenous insulin based on the carbohydrate content of their meals. However, carbohydrate counting is error-prone, resulting in sub-optimal glucose control. Type 1 Diabetics are also deficient in the hormone, amylin which helps regulate blood sugar levels by delaying food absorption, glucagon secretion and increasing satiety. The synthetic analog of amylin, pramlintide, is FDA-approved. We aim to conduct a clinical trial to alleviate carbohydrate counting using our novel fully closed loop automated insulin delivery system (AID) with pramlintide as an adjunctive therapy. Participants will use a continuous glucose monitor, insulin and pramlintide pumps and our EuGlide application. Our AID system will integrate these devices to automate insulin (and pramlintide) delivery based on an individual’s glucose readings with no user input required. In this cross-over trial, 30 adults with type 1 diabetes will undergo three weeks of each of the following interventions, fully automated insulin-and-pramlintide delivery at (i) 8µg/u and (ii) 10 µg/u ratios and (iii) hybrid automated insulin-and-placebo delivery system with carbohydrate counting. Participants will undergo interviews and questionnaires to assess psychosocial outcomes and their quality of life. If our study shows non-inferiority in the time in target range between interventions, we conclude that the fully automated insulin-and-pramlintide delivery system does not degrade glucose outcomes compared to the hybrid automated delivery system. We hope that our novel AID system eliminates carbohydrate counting and alleviates disease burden by automating insulin delivery.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Doumat, Joelle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~